BURLINGTON, Mass.--()--Decision Resources Group is pleased to announce a distinguished lineup of speakers who will be joining its well-regarded Competitive Landscape Seminar Series focusing on Biologics and Biosimilars on October 4, 2012 at Le Parker Meridien New York in New York City. The panel discussion will focus on the future success and challenges facing the biologics and biosimilars market.
Moderated by Andrew Merron, Ph.D., Director, Biosimilars & Oncology Products, BioTrends Research Group, panelists include:
- Lon Castle, M.D., Senior Director, Clinical Innovation, Express Scripts, Inc.
- John L. Fox, M.D., M.H.A., Associate Vice President of Medical Affairs, Priority Health of Michigan
- Jay Schechtman, M.D., M.B.A., from HealthFirst, Inc. of New York
Panelists will focus on the keys issues affecting the biologics landscape and the emerging biosimilars sector based on the European experience of biosimilars to date and expectations for the U.S. Topics to be discussed will include the anticipated future trends in the biologics market and the challenges and drivers of biosimilar adoption in the U.S. Panelists will share their thoughts on market access for biosimilars, the role of indication extrapolation and automatic substitution, as well as their perspective on appropriate pricing models for brands and biosimilars as this dynamic market segment continues to evolve.
For more information and to register, please visit: http://www.competitivelandscapeseries.com/biologics-and-biosimilars
Media interested in attending the seminar should contact Briana Pontremoli at firstname.lastname@example.org or 781-993-2654 for additional information.
About the Competitive Landscape Seminar Series
The Competitive Landscape Seminar Series: Biologics and Biosimilars will be held on October 4, 2012. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.